Levels of g1ycoprotein:sialyltransferase activity (EC 2.4.99.1 ; CMP-acetylneuraminate:D-galactosyl-glycoprotein N-acetylneuraminyl-transferase) were measured in plasma of patients with neoplastic disease, and were found elevated above normal control values in 85% of patients examined. There was a correlation between enzyme levels and course of disease in 46 of 57 patients studied serially during therapy. Plasma sialyltransferase may be a useful marker enzyme for monitoring effectiveness of therapeutic programs for disseminated neoplasms.Cancer 39:1129-1134, 1977.
GROUP OF CELLULAR ENZYMES CALLED GLY-A cosyltransferases sequentially add individual monosaccharides to appropriate protein and glycoprotein acceptors. One such enzyme, a sialyltransferase, can catalyze incorporation of sialic acid from the nucleotide sugar cytidine monophosphate sialic acid (CMP-sialic acid) onto the galactose residue of desialated fetuin. 'I Sialyltransferase activity has also been found in plasma and serum in man"," and animals.' In several laboratories, effects of neoplastic transformation upon cell sialyltransferase levels have been examined: the results show considerable variation, with both d e~r e a s e d~-~* '~, ' ' and elevated'.'' enzyme levels reported. In studies involving tumor tissue of human origin, both reduced10.12 and elevated3 transferase levels were found associated with neoplastic tissue, compared with its normal counterpart.From the foregoing information, the effect of neoplasia on plasma sialyltransferase levels is difficult to predict. This enzyme was found elevated in plasma of tumor-bearing rats' and in cancer patients."." In a previous report'a correlation was found between plasma sialyltransferase and response to chemotherapy in a single cancer patient. In this report, we describe results of experiments over a 10-month period involving a study of 134 cancer patients, of whom 57 were serially followed during therapeutic programs. We found a correlation between progression of disease and plasma sialyltransferase levels in 80% of these evaluable patients.
MATERIALS AND METHODS
Plasma PreparationsBlood was collected in citrate tubes from normal donors and cancer patients. The plasma was separated by centrifugation, and used after brief storage at -40'. N o attempt was made to standardize time of day or prandial status of patients when the specimen was taken.
Enzyme AssaySialyltransferase was measured in a 120 ul mixture containing 25 ul of plasma (2-3 mg of protein), 12 ul of 100 m M MnCI,, 6 ul of 1 M HEPES or cacodylate buffer pH 6.3, 12 ul of 1 % Triton X-100, 0.5 mg of desialated" fetuin or other acceptor, dissolved in 50 ul of water and 1 or 25 nmol of CMP-['C]-sialic acid ( 7 or 215 mCi/mmol). This mixture represents an optimal system with regard to pH, metal ion concentration and acceptor level. Total radioactivity present was approximately 56,000 counts/min/ 120 ul. Incorporation of radioactivity into acid-insoluble material was measured. 3 , 4 3 8 Plasma protein was measured by the Lowry method." In so...